Recombinant Factor C (rFC) vs LAL Assay: Comparability and Regulatory Trends in Endotoxin Testing

Try Our Recombinant Factor C Endotoxin Testing Kit (RES-A056) for Free!

Click to Apply Now!

Background

Bacterial endotoxin testing (BET) is a critical component of quality control in biopharmaceutical production. Traditionally, the Limulus Amebocyte Lysate (LAL) assay has been the gold standard. However, the LAL method relies heavily on horseshoe crab blood, raising concerns about supply chain stability, animal welfare, and false positives due to β-glucan interference with Factor G pathways.

As a sustainable, animal-free endotoxin testing alternative, the Recombinant Factor C (rFC) method utilizes genetically engineered Factor C proteins to specifically recognize lipopolysaccharide (LPS), the active component of endotoxins. Without activation of secondary pathways, rFC ensures greater specificity and is increasingly supported by global pharmacopeias and regulatory bodies.

As regulatory acceptance expands, the comparison between rFC and traditional LAL assays has become a major focus in endotoxin testing strategy and method validation.

Performance Comparison Between rFC and LAL Endotoxin Assays

(1) Sensitivity and Consistency

Multiple studies have demonstrated that rFC is highly comparable to LAL in sensitivity. For instance:

• In samples such as non-potable water, clean steam, and water for injection (WFI), both methods achieved 50–200% recovery rates.

• rFC and LAL showed identical non-detection rates for WFI and clean steam samples.

• In testing 41 waterborne bacterial contamination samples, rFC and LAL results over 85% consistency, around to the 95% variation observed between LAL assay.

(2) Resistance to Interference

rFC operates solely via the Factor C pathway, avoiding interference from β-glucans and other non-endotoxin substances. This minimizes false positives and makes it better suited for complex sample matrices.

In vaccine production, intermediate products often contain high levels of recombinant proteins or detergents that inhibit LAL performance. rFC, with optimized pre-treatment (e.g., dilution), can accurately quantify endotoxins in these challenging samples.

(3) Quantification and Trend Analysis

rFC demonstrates a high correlation with LAL (R² > 0.98) when using kinetic chromogenic methods, supporting process monitoring and trend analysis.

Moreover, rFC maintains reliable detection of endotoxins from bacteria grown in low-nutrient environments like M9 medium, where LAL may require greater dilution due to complex sample backgrounds.

Comparison of LAL Assay and Recombinant Factor C Assay Detection Procedures

Regulatory Landscape and Method Validation of rFC

(1) Global Pharmacopeial Adoption

• European Pharmacopoeia (Ph. Eur.): The European Pharmacopoeia officially incorporated recombinant Factor C as an independent endotoxin testing method in Chapter 2.6.32 in 2021.

• United States Pharmacopeia (USP): USP has progressively advanced recombinant endotoxin testing standards. USP Chapter <86>, approved in July 2024 and effective from May 2025, formally permits the use of recombinant Factor C (rFC) for bacterial endotoxin testing. The chapter outlines key validation requirements, including interference testing, accuracy and precision evaluation, linearity assessment, and method suitability verification.

• Japanese Pharmacopoeia (JP): Japan has actively advanced recombinant endotoxin testing through comparative studies and expert discussions. Current guidance includes procedures for endotoxin testing using recombinant protein reagents.

(2) Key Validation Requirements

• Interference Testing: Validate recoveries within 50–200% at the maximum valid dilution (MVD). If interference (e.g., low endotoxin recovery) occurs, optimize sample prep via ultrafiltration or chelating agents.

• Comparability Protocols: According to USP<1225>, switching methods or suppliers require comparability data. The FDA classifies such changes under CBE-0 or CBE-30 submission pathways.

Advantages of rFC in Endotoxin Testing

• Stable Supply Chain: Biotechnologically produced rFC avoids reliance on horseshoe crabs and aligns with the 3Rs principle (Replacement, Reduction, Refinement).

• High Specificity: Eliminates interference from β-glucans, fungal polysaccharides, or plant-derived components—ideal for samples filtered through cellulose or containing botanical extracts.

• Regulatory Momentum: Already accepted by the Ph. Eur. and encouraged by the FDA in early clinical phases to mitigate risk.

Looking Ahead

Recombinant Factor C (rFC) offers superior sensitivity, specificity, and sustainability compared to traditional LAL reagents, making it especially suitable for complex samples and global manufacturing environments. With USP<86>now in effect, a new era of harmonized global standards for endotoxin testing is underway. Looking ahead, rFC is well-positioned to gradually replace LAL as the mainstream method—delivering a more robust solution for endotoxin control in complex biologics such as cell therapies.

Recombinant Factor C Endotoxin Testing Solution

ACROBiosystems has developed a recombinant Factor C Endotoxin Testing kit (Cat. No. RES-A056) based on endpoint fluorescence detection. Tailored for pharmaceuticals, medical devices, and biologic products, this kit supports rigorous QC standards across the industry.

Core Advantages

• Fully validated Recombinant Factor C method (Ph. Eur. 11.0 and USP<1225> guidelines).USP<86> has officially recognized the Recombinant Factor C (rFC) assay for Endotoxin Testing.

• High concordance with traditional LAL methods, third-party validation available.

• Superior specificity: Effectively eliminates β-glucan interference.

• High accuracy: Endotoxin standards traceable to USP Standard (Cat. No: 1235503).

• Rapid results: Assay completion in under an hour.

• Industry-leading sensitivity: Detects endotoxin from 0.005 - 5 EU/mL.

Learn More

Validation Data

High sensitivity, detection results comparable to LAL method

Different methods were used to detect endotoxin residues in four samples, and the deviation between the detection results of rFC method and LAL method is within 2 times.

Free Resources Here

FAQ

Q: Is rFC equivalent to LAL for endotoxin testing?

A: Studies have shown that rFC demonstrates comparable sensitivity and recovery performance to traditional LAL assays across multiple sample types.

Q: Does USP <86> approve recombinant Factor C?

A: USP <86> recognizes recombinant reagents including rFC for bacterial endotoxin testing with appropriate validation.

Q: Why is rFC considered more specific than LAL?

A: rFC specifically activates the Factor C pathway and avoids β-glucan-mediated false positives associated with Factor G activation.

Recommended Products

• Mycoplasma Rapid Detection Kit

• Host DNA Residue Detection Kits

• T7 RNA Polymerase Residue Detection Kit

• DNase Activity Assay Kit (Fluorescence)

• resDetect™ Process Residue Detection Solutions

Upcoming Endotoxin Testing Insights Series:

Part 1: Strategies for Mitigating β-Glucan Interference in Endotoxin Testing

Part 2: Application of Recombinant Factor C Endotoxin Testing in Pharmaceutical Manufacturing

Part 3: Standards and Regulations for Recombinant Factor C Endotoxin Testing from a Pharmacopoeial Perspective

Part 4: Comparison of Recombinant Factor C and Other LAL Methods

Part 5: A Comprehensive Guide to Sample Dilution Calculations for Recombinant Factor C Endotoxin Testing

Part 6: Key Considerations for Endotoxin Testing Experimental Procedures

Part 7: Interfering Factors in Endotoxin Testing